[3H]vesamicol binding in human brain cholinergic deficiency disorders.

  title={[3H]vesamicol binding in human brain cholinergic deficiency disorders.},
  author={Stephen J. Kish and L. Distefano and Slobodan Dozi{\'c} and Yves O Robitaille and Alex Rajput and John H. N. Deck and Oleh Hornykiewicz},
  journal={Neuroscience letters},
  volume={117 3},
We measured the binding of the vesicular acetylcholine transport blocker [3H]vesamicol (2-[4-phenylpiperidino] cyclohexanol; AH-5183) to autopsied frontal cortex and amygdala of patients from 4 disorders having a marked brain cholinergic reduction, namely Alzheimer's disease, Parkinson's disease with dementia, dominantly inherited olivopontocerebellar atrophy and Down's syndrome. Although mean activity of the specific cholinergic marker enzyme choline acetyltransferase (ChAT) was markedly… CONTINUE READING